Halozyme Therapeutics Inc Net Income per Employee (HALO), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Halozyme Therapeutics Inc   (NASDAQ: HALO)
 

Halozyme Therapeutics Inc Net Income per Employee

HALO's Quarterly Results, Trends, Rankings, Statistics
With an income increase of 39.21% in the second quarter 2026, year on year to cumulative value of $414 million, and with 423 employees, Halozyme Therapeutics Inc 's income per employee grew on trailing twelve month basis to $ 977,768. The income per employee at Halozyme Therapeutics Inc ' was above the company average.
The Healthcare sector has seen employees of 5 other companies achieving higher income per employee. While income per employee total ranking has improved so far to 228, from total ranking in previous quarter at 332.


What is Income per Employee Ratio?





Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

HALO Net Income per Employee (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Net Income Change 39.21 % 27.06 % - 27.89 % 77.12 %
Net Income per Employee (TTM) $ 977,768 824,688 749,147 1,407,783 1,317,442
HALO's Total Ranking # 228 # 332 # 153 # 151 # 159
Seq. Net Income Change 53.23 % - - 6.09 % 39.85 %

HALO Company Profile >> Back to HALO Efficiency Comparisons >> Compare HALO Net Income per Employee to its Competitors

HALO Net Income per Employee Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 6
Healthcare Sector # 33
Overall Market # 228

Net Income per Employee Statistics
High Average Low
$ 1,407,783 $ 250,509 $ -283,669
(Sep 30 2025)   (Jun 30 2017)







Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector Income per Employee Income 12 month ending Jun 30 2026Number of Employees Jun 30 2026
Actinium Pharmaceuticals Inc  1,514,120.00 $ 37.853  Million 25 
Q32 Bio Inc   1,407,750.00 $ 33.786  Million 24 
Ironwood Pharmaceuticals inc   1,298,680.00 $ 129.868  Million 100 
Agenus Inc  1,135,037.04 $ 91.938  Million 81 
Tg Therapeutics Inc   1,106,491.23 $ 441.490  Million 399 
Halozyme Therapeutics Inc   977,768.32 $ 413.596  Million 423 
Zevra Therapeutics Inc   949,245.90 $ 57.904  Million 61 
Protagenic Therapeutics Inc new  910,314.00 $ 5.462  Million 6 
Elite Pharmaceuticals Inc   871,814.86 $ 56.668  Million 65 
The Greater Cannabis Company Inc   740,754.00 $ 0.741  Million 1 
Omeros Corporation  713,291.43 $ 124.826  Million 175 
Prestige Consumer Healthcare Inc   712,757.89 $ 406.272  Million 570 
Atlantic Coastal Acquisition Corp Ii  670,333.33 $ 2.011  Million 3 
Illumina Inc   644,531.25 $ 825.000  Million 1,280 
Liquidia Corporation  641,694.44 $ 138.606  Million 216 
Harmony Biosciences Holdings inc   618,668.94 $ 181.270  Million 293 
Protagonist Therapeutics inc   616,272.73 $ 81.348  Million 132 
Theravance Biopharma inc   597,866.67 $ 53.808  Million 90 
Vaxart Inc   593,676.92 $ 38.589  Million 65 
Glucotrack Inc   554,600.00 $ 8.319  Million 15 
Silexion Therapeutics Corp  489,714.29 $ 6.856  Million 14 


Date modified: 2026-09-08T01:18:12+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.